Wanbury Limited achieved its highest-ever operational EBITDA of ₹108 crore in FY26, marking a successful turnaround and the onset of growth momentum. The pharmaceutical company reported a total revenue of ₹650 crore for the financial year, with the API business contributing ₹574 crore and the formulations business adding ₹76 crore. This performance was underpinned by operational efficiencies, debottlenecking, and balance sheet improvements, including a moderate leverage ratio of ~2X Debt/EBITDA.

Business Performance

The API segment, which accounts for 88% of the total revenue mix, recorded an 8% year-on-year growth. This business stream focuses on developed markets including the EU, Brazil, and the US, with 80% of the top line derived from exports. The company holds significant global market share in key products such as Metformin and Sertraline. In contrast, the formulations business, which is in a rebuilding phase, saw a 12% year-on-year decline in revenue to ₹76 crore. Management attributed the revenue dip in the fourth quarter to the West Asia crisis impacting API export dispatches in March.

Operational Milestones

A key milestone for the year was the launch of a new Anaesthetic API, with commercial dispatches beginning in February 2026. The company also cleared the MFDS Korea inspection with zero observations, validating its compliance systems. Wanbury continued to strengthen its regulatory credentials, maintaining approvals from USFDA, EDQM, ANVISA, and WHO GMP across its manufacturing facilities. The cumulative installed reactor capacity stands at 500 KL, with a potential for an additional 600 KL at existing sites.

Strategic Outlook

Management stated that FY26 was a pivotal year for strengthening business fundamentals. Looking ahead, the company plans to continue its API growth journey in FY27 with recent launches and a strong pipeline of four molecules scheduled for commercialisation each year. For the formulations business, the strategy focuses on leveraging its heritage to rebuild a scalable franchise, transitioning the portfolio towards speciality and chronic segments, and achieving profitability break-even in FY26 through better scale and cost-management efforts.

Financial Snapshot

Wanbury Ltd’s board has approved the incorporation of a new subsidiary, Wanbury Skin Health Limited, to expand its presence in the pharmaceutical industry. The board, meeting on June 26, 2026, sanctioned an estimated aggregate capital outlay of ₹4,10,000 for the new entity. This strategic move involves the subscription to 41,000 equity shares with a face value of ₹10 each, giving the parent company an 82% stake in the subsidiary upon incorporation.

The incorporation is subject to necessary approvals from the Registrar of Companies and other relevant regulatory authorities. Wanbury Ltd will subscribe to the shares via cash consideration at face value. The company stated that all investments in the subsidiary would be disclosed to stock exchanges in compliance with SEBI Listing Regulations and the Companies Act, 2013.

In addition to the corporate expansion, the board appointed statutory auditors for the financial year 2026-2027. M/s. Ernst & Young LLP was appointed as the Internal Auditor, while M/s. ABK & Associates was appointed as the Cost Auditor. Both appointments are for a term of one year.

The board meeting commenced at 3:35 p.m. and concluded at 4:15 p.m. on June 26, 2026. The decisions were taken pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Approvals